Tenax Therapeutics (TENX) Capital Expenditures (2010 - 2023)

Tenax Therapeutics (TENX) posted quarterly Capital Expenditures of $1602.0 for Q2 2023, up 29.09% on a QoQ basis from $1241.0 in Q1 2023.

Tenax Therapeutics (TENX) Capital Expenditures (2010 - 2023) Analysis & Trends

Tenax Therapeutics has reported Capital Expenditures for 14 years, with the latest figure at $1602.0 in Q2 2023.

Capital Expenditures for Q2 2023 came in at $1602.0, changed N/A year-over-year; the trailing twelve-month figure through Jun 2023 was -$1157.0 (down 111.93% YoY), and the FY2022 annual result was $2323.0, down 55.77% from the prior year.
Capital Expenditures climbed to $1602.0 in Q2 2023, from $1241.0 in the prior quarter.
Over five years, Capital Expenditures peaked at $6323.0 in Q1 2022 and troughed at -$4000.0 in Q4 2022.
A 5-year average of $1942.4 and a median of $1698.0 in 2021 frame the typical range for Capital Expenditures.
The widest annual swing landed in 2019, when Capital Expenditures rose 15.1%; it then tumbled 335.57% in 2022.
A 5-year view of Capital Expenditures shows it stood at $3574.0 in 2019, then decreased by 2.35% to $3490.0 in 2020, then plunged by 51.35% to $1698.0 in 2021, then tumbled by 335.57% to -$4000.0 in 2022, then jumped by 140.05% to $1602.0 in 2023.
Per Business Quant data, the three most recent Capital Expenditures figures were $1602.0 in Q2 2023, $1241.0 in Q1 2023, and -$4000.0 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	34.68 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	6.26 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	251.02 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-73.57 Mn
10	Tenax Therapeutics	80.73 Mn	80.73 Mn	-	-

Download Data